These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25995185)

  • 21. Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance.
    Freed BH; Narang A; Bhave NM; Czobor P; Mor-Avi V; Zaran ER; Turner KM; Cavanaugh KP; Chandra S; Tanaka SM; Davidson MH; Lang RM; Patel AR
    J Cardiovasc Magn Reson; 2013 Dec; 15(1):108. PubMed ID: 24359617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification with vasodilator stress SPECT myocardial perfusion imaging in patients with elevated cardiac biomarkers.
    Gowdar S; Ahlberg AW; Rai M; Perucki WH; Felpel KD; Savino JA; Alter EL; Henzlova MJ; Duvall WL
    J Nucl Cardiol; 2020 Dec; 27(6):2320-2331. PubMed ID: 30815834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients.
    Kazmirczak F; Nijjar PS; Zhang L; Hughes A; Chen KA; Okasha O; Martin CM; Akçakaya M; Farzaneh-Far A; Shenoy C
    J Cardiovasc Magn Reson; 2019 Jan; 21(1):9. PubMed ID: 30674318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pituitary apoplexy after regadenoson myocardial perfusion scan.
    Shetty S; Gnanaraj J; Jayamani Roshan S; El Accaoui R
    J Nucl Cardiol; 2020 Feb; 27(1):336-339. PubMed ID: 30168027
    [No Abstract]   [Full Text] [Related]  

  • 25. Regadenoson Stress Perfusion Cardiac Magnetic Resonance Imaging in Children With Kawasaki Disease and Coronary Artery Disease.
    Doan TT; Wilkinson JC; Loar RW; Pednekar AS; Masand PM; Noel CV
    Am J Cardiol; 2019 Oct; 124(7):1125-1132. PubMed ID: 31371063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.
    Mahmarian JJ; Cerqueira MD; Iskandrian AE; Bateman TM; Thomas GS; Hendel RC; Moye LA; Olmsted AW
    JACC Cardiovasc Imaging; 2009 Aug; 2(8):959-68. PubMed ID: 19679284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regadenoson: a focused update.
    Ghimire G; Hage FG; Heo J; Iskandrian AE
    J Nucl Cardiol; 2013 Apr; 20(2):284-8. PubMed ID: 23229649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of
    Brophey MD; Farukhi IM; Castanon R; DeLaPena R; Bradshaw L; Banerjee S
    J Nucl Med Technol; 2017 Jun; 45(2):75-81. PubMed ID: 28408703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Off-label, but on-target: use of regadenoson with exercise.
    Hendel RC; Frost L
    J Nucl Cardiol; 2013 Apr; 20(2):179-81. PubMed ID: 23143811
    [No Abstract]   [Full Text] [Related]  

  • 30. Differential risk reclassification improvement by exercise testing and myocardial perfusion imaging in patients with suspected and known coronary artery disease.
    Koh AS; Gao F; Chin CT; Keng FY; Tan RS; Chua TS
    J Nucl Cardiol; 2016 Jun; 23(3):366-78. PubMed ID: 26358085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm.
    Iskander F; Iskander M; Gomez J; Doukky R
    J Nucl Cardiol; 2021 Jun; 28(3):967-977. PubMed ID: 31144225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asystole following regadenoson infusion in stable outpatients.
    Rosenblatt J; Mooney D; Dunn T; Cohen M
    J Nucl Cardiol; 2014 Oct; 21(5):862-8. PubMed ID: 24879452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serious complications associated with regadenoson administration for myocardial perfusion imaging.
    Kitt T; Jiang J
    J Nucl Cardiol; 2015 Apr; 22(2):395. PubMed ID: 25548120
    [No Abstract]   [Full Text] [Related]  

  • 34. Regadenoson.
    Garnock-Jones KP; Curran MP
    Am J Cardiovasc Drugs; 2010; 10(1):65-71. PubMed ID: 20063904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left ventricular ejection fraction, myocardial blood flow and hemodynamic variables in adenosine and regadenoson vasodilator 82-Rubidium PET.
    Frey SM; Honegger U; Clerc OF; Caobelli F; Haaf P; Zellweger MJ
    J Nucl Cardiol; 2022 Jun; 29(3):921-933. PubMed ID: 34386864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson.
    Qamruddin S; Huang HW; Mehra A; Bonyadlou S; Yoon AJ
    Clin Nucl Med; 2016 Jan; 41(1):62-4. PubMed ID: 26447370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serious complications associated with regadenoson administration for myocardial perfusion imaging: a commentary.
    Hage FG; Iskandrian AE
    J Nucl Cardiol; 2014 Oct; 21(5):877-9. PubMed ID: 25156654
    [No Abstract]   [Full Text] [Related]  

  • 38. Rapid rest/stress regadenoson ungated perfusion CMR for detection of coronary artery disease in patients with atrial fibrillation.
    Bieging ET; Haider I; Adluru G; Chang L; Suksaranjit P; Likhite D; Shaaban A; Jensen L; Wilson BD; McGann CJ; DiBella E
    Int J Cardiovasc Imaging; 2017 Nov; 33(11):1781-1788. PubMed ID: 28528431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantification of myocardial perfusion in clinical trials.
    Petretta M; Nappi C; Cuocolo A
    J Nucl Cardiol; 2015 Apr; 22(2):262-5. PubMed ID: 25287736
    [No Abstract]   [Full Text] [Related]  

  • 40. Marked ST-segment elevations during regadenoson pharmacologic nuclear stress testing.
    Chan N; Kataria V; Kim BS; Raimondi P; Makaryus JN
    J Nucl Cardiol; 2020 Jun; 27(3):1071-1075. PubMed ID: 30887384
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.